

PACE

Prescriber Information

November 3, 2008

Future PACE edits

This information is being included with mailings to PACE prescribers to advise them of two PACE edits that will be implemented in January, 2009.

Effective January 1, 2009:

AVANDIA®-- all new prescriptions for rosiglitazone (Avandia®) will be denied at the point of sale for cardholders not enrolled in a Part D plan.

ACTOS®-- all new prescriptions for pioglitazone (Actos®) will be denied at the point of sale for cardholders not enrolled in a Part D plan unless the cardholder's PACE claim's history contains claims for metformin, a sulfonylurea or insulin within the last 60 days.



PACE will NOT be granting any pharmacist requested medical exceptions for either AVANDIA® or ACTOS®.

Following these denials at the pharmacy, a letter will be sent to the prescriber identified on the claim requesting documentation supporting the prescribing of either Avandia® or Actos®. Upon receipt of this documentation, consideration of a medical exception will be made.

Prescribers may direct questions to PACE Drug Utilization Review (DUR) at
1-800-242-1338.